Skip to main content

Advertisement

SpringerLink
Log in

Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells

  • ORIGINAL CONTRIBUTION
  • Published:
Basic Research in Cardiology Aims and scope Submit manuscript

Abstract

Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and by obstructive changes of the pulmonary vasculature including smooth muscle cell proliferation which leads to medial hypertrophy and subsequent luminal narrowing. Sildenafil, an orally active inhibitor of cGMP phosphodiesterase–type–5, exerts pulmonary vasodilator activity in PAH patients. We evaluated the effects of sildenafil on growth of cultured human pulmonary artery smooth muscle cells (PASMC). The results indicate that sildenafil reduced DNA synthesis stimulated by PDGF and dose dependently inhibited PASMC proliferation. These effects were paralleled by a progressive increase in cGMP content, followed by an accumulation of cAMP. The treatment with 8–bromo–cGMP or dibutyryl–cAMP mimicked all the effects of sildenafil. On the other hand, treatment of PASMC with inhibitors of cGMP–dependent protein kinase (PKG) or cAMP–dependent protein kinase (PKA) reversed the antiproliferative effect of sildenafil. In addition, sildenafil inhibited the phosphorylation of ERK, a converging point for several pathways leading to cell proliferation. This effect was partially reduced by PKG inhibition and completely abolished by PKA inhibition.

We conclude that sildenafil exerts an antiproliferative effect on human PASMC that is mediated by an interaction between the cGMP–PKG and the cAMP–PKA activated pathways, leading to inhibition of PDGF–mediated activation of the ERK.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD (2003) Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78:1207–1213

    CAS  PubMed  Google Scholar 

  2. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C (1996) Sildenafil: an orally active type-5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47–52

    CAS  PubMed  Google Scholar 

  3. Bradford MH (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254

    CAS  PubMed  Google Scholar 

  4. Cook SJ, McCormick F (1993) Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069–1072

    CAS  PubMed  Google Scholar 

  5. Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729–13732

    Article  CAS  PubMed  Google Scholar 

  6. Fukumoto S, Koyama H, Hosoi M, Yamakawa K, Tanaka S, Morii H, Nishizawa Y (1999) Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ Res 85:985–991

    CAS  PubMed  Google Scholar 

  7. Galiè N, Manes A, Branzi A (2003) Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2:123–137

    PubMed  Google Scholar 

  8. Galiè N, Manes A, Branzi A (2004) The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61:227–237

    Article  PubMed  Google Scholar 

  9. Galiè N, Manes A, Uguccioni L, Serafini F, De Rosa M, Branzi A, Magnani B (1998) Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest 114:184S–194S

    PubMed  Google Scholar 

  10. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522

    CAS  PubMed  Google Scholar 

  11. Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG (1993) Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA 90:10300–10304

    Google Scholar 

  12. Gurujeyalakshmi G, Hollinger MA, Giri SN (1999) Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 276 :L311–L318

    CAS  PubMed  Google Scholar 

  13. Jeffery TK, Wanstall JC (2001) Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92:1–20

    Google Scholar 

  14. Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y (2001) Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 186:1–10

    Google Scholar 

  15. Michelakis Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL (2003) Long-Term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:2066–2069

    Google Scholar 

  16. Nelson PR, Yamamura S, Mureebe L, Itoh H, Kent KC (1998) Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogenactivated protein kinase. J Vasc Surg 27:117–125

    CAS  PubMed  Google Scholar 

  17. Osinski MT, Rauch BH, Schror K (2001) Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 59:1044–1050

    CAS  PubMed  Google Scholar 

  18. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM (1989) Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the NIH, Primary Pulmonary Hypertension Registry. Circulation 80:1198–1206

    Google Scholar 

  19. Pilz RB, Casteel DE (2003) Regulation of gene expression by cyclic GMP. Circ Res 93:1034–1046

    Article  CAS  PubMed  Google Scholar 

  20. Piper AS, Large WA (2004) Direct effect of Ca2+-calmodulin on cGMP-activated Ca2+-dependent Cl-channels in rat mesenteric artery myocytes. J Physiol 559:449–457

    Article  CAS  PubMed  Google Scholar 

  21. Polson JB, Strada SJ (1996) Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 36:403–427

    CAS  PubMed  Google Scholar 

  22. Rabinovitch M (1998) Elastase and pathobiology of unexplained pulmonary hypertension. Chest 114:213S–224S

    CAS  PubMed  Google Scholar 

  23. Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336 (2):111–117

    Article  CAS  PubMed  Google Scholar 

  24. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280–291

    Article  CAS  PubMed  Google Scholar 

  25. Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. Journal of the American College of Cardiology 43:1149–1153

    Google Scholar 

  26. Satoh S, Makino N (2001) Intracellular mechanisms of cGMP-mediated regulation of myocardial contraction. Basic Res Cardiol 96:652–658

    CAS  PubMed  Google Scholar 

  27. Simonneau G, Galie N, Rubin L, Langleben D, Seeger W, Dominighetti G, Gibbs S, Lebrec D, Speich S, Beghetti M, Rich S, Fishman A (2004) Epidemiology and Clinical Classification of Pulmonary Arterial Hypertension. J Am Coll Cardiol 43:5S–12S

    Article  PubMed  Google Scholar 

  28. Southgate K, Newby AC (1990) Seruminduced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 82:113–123

    CAS  PubMed  Google Scholar 

  29. Stenmark KR, Mecham RP (1997) Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 59:89–144

    CAS  PubMed  Google Scholar 

  30. Suhasini M, Li H, Lohmann SM, Boss GR, Pilz RB (1998) Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogenactivated protein kinase pathway. Mol Cell Biol 18:6983–6994

    CAS  PubMed  Google Scholar 

  31. Tantini B, Flamigni F, Pignatti C, Stefanelli C, Fattori M, Facchini A, Giordano E, Clo’ C, Caldarera CM (2001) Polyamines, NO and cGMP mediate stimulation of DNA synthesis by tumor necrosis factor and lipopolysaccharide in chick embryo cardiomyocytes. Cardiovasc Res 49:408–416

    Article  CAS  PubMed  Google Scholar 

  32. Tantini B, Pignatti C, Fattori M, Flamigni F, Stefanelli C, Giordano E, Menegazzi M, Clô C, Caldarera CM (2000) NF-kappaB and ERK cooperate to stimulate DNA synthesis by inducing ornithine decarboxylase and nitric oxide synthase in cardiomyocytes treated with TNF and LPS. FEBS Lett 512:75–79

    Article  Google Scholar 

  33. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW (1993) Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3’,5’-monophosphate. Science 262:1065–1069

    CAS  PubMed  Google Scholar 

  34. Yu SM, Hung LM, Lin CC (1997) cGMPelevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 95:1269–1277

    Google Scholar 

  35. Zhang S, Remillard CV, Fantozzi I, Yuan JX (2004) ATP-induced mitogenesis is mediated by CREB-enhanced TRPC4 expression and activity in human pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol Jun 30 (in press)

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, “G. Moruzzi” University of Bologna, via Irnerio, 48, 40126-Bologna, Italy

    B. Tantini PhD, E. Fiumana PhD, C. Pignatti PhD & C. Guarnieri PhD

  2. Institute of Cardiology, University of Bologna, Bologna

    A. Manes MD, R Zannoli PhD, A. Branzi MD & N. Galiè MD

Authors
  1. B. Tantini PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Manes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Fiumana PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Pignatti PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Guarnieri PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Zannoli PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Branzi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Galiè MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Tantini PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tantini, B., Manes, A., Fiumana, E. et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100, 131–138 (2005). https://doi.org/10.1007/s00395-004-0504-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00395-004-0504-5

Key words

Search

Navigation